Post by Reuters Legal

Johnson & Johnson's medical device subsidiary Abiomed has won a jury trial in Massachusetts over allegations that it violated Maquet Cardiovascular's patent rights in heart-pump technology. Abiomed convinced the jury on May 28 that ‌its Impella intravascular heart pumps used to treat heart failure did not infringe a patent related to competing pumps made by Maquet, an Abiomed attorney told Reuters on May 29. The jury also determined that the patent was invalid, the attorney said. A J&J spokesperson said ​that the verdict 'vindicates what we have maintained all along: Abiomed invented a life-saving heart ​pump and Maquet’s patent cannot be stretched so far as to capture Abiomed’s innovation.' Abiomed's first Impella models received FDA approval in 2008. Johnson & Johnson struck a $16.6 billion all-cash deal ​in 2022 to buy Abiomed, which specializes in heart pumps, to boost growth ​in its medical devices unit. Blake Brittain has more: https://reut.rs/4wS3LuZ